<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article article-type="research-article" dtd-version="3.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0149541</article-id>
<article-id pub-id-type="publisher-id">PONE-D-15-50282</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Mutation</subject><subj-group><subject>Insertion mutation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Bacteria</subject><subj-group><subject>Staphylococcus</subject><subj-group><subject>Staphylococcus aureus</subject><subj-group><subject>Methicillin-resistant Staphylococcus aureus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Bacterial pathogens</subject><subj-group><subject>Staphylococcus</subject><subj-group><subject>Staphylococcus aureus</subject><subj-group><subject>Methicillin-resistant Staphylococcus aureus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Bacterial pathogens</subject><subj-group><subject>Staphylococcus</subject><subj-group><subject>Staphylococcus aureus</subject><subj-group><subject>Methicillin-resistant Staphylococcus aureus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Bacteria</subject><subj-group><subject>Staphylococcus</subject><subj-group><subject>Staphylococcus aureus</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Bacterial pathogens</subject><subj-group><subject>Staphylococcus</subject><subj-group><subject>Staphylococcus aureus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Bacterial pathogens</subject><subj-group><subject>Staphylococcus</subject><subj-group><subject>Staphylococcus aureus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Computational biology</subject><subj-group><subject>Genome analysis</subject><subj-group><subject>Genomic libraries</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Genomics</subject><subj-group><subject>Genome analysis</subject><subj-group><subject>Genomic libraries</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drugs</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibiotics</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial control</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibiotics</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical compounds</subject><subj-group><subject>Thymidines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Mutation</subject><subj-group><subject>Mutant strains</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene identification and analysis</subject><subj-group><subject>Mutation detection</subject></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Whole-Genome Sequencing of Methicillin-Resistant <italic>Staphylococcus aureus</italic> Resistant to Fifth-Generation Cephalosporins Reveals Potential Non-<italic>mecA</italic> Mechanisms of Resistance</article-title>
<alt-title alt-title-type="running-head">Potential Non-<italic>mecA</italic> Mechanisms of Resistance in MRSA Identified by Whole-Genome Sequencing</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
<name name-style="western">
<surname>Greninger</surname>
<given-names>Alexander L.</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
<name name-style="western">
<surname>Chatterjee</surname>
<given-names>Som S.</given-names>
</name>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Chan</surname>
<given-names>Liana C.</given-names>
</name>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Hamilton</surname>
<given-names>Stephanie M.</given-names>
</name>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Chambers</surname>
<given-names>Henry F.</given-names>
</name>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Chiu</surname>
<given-names>Charles Y.</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, United States of America</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, California, United States of America</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Division of Infectious Diseases, Department of Medicine, San Francisco General Hospital, San Francisco, California, United States of America</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Tang</surname>
<given-names>Patrick</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Sidra Medical and Research Center, QATAR</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>CYC is the director of the UCSF-Abbott Viral Diagnostics and Discovery Center (VDDC) and receives research support in pathogen discovery from Abbott Laboratories, Inc. The other authors have declared that no competing interests exist. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.</p>
</fn>
<fn fn-type="con" id="contrib001">
<p>Conceived and designed the experiments: ALG SSC HFC CYC. Performed the experiments: ALG SSC LCC SMH. Analyzed the data: ALG SSC HFC CYC. Contributed reagents/materials/analysis tools: HFC CYC. Wrote the paper: ALG SSC HFC CYC.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">charles.chiu@ucsf.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>18</day>
<month>2</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<year>2016</year>
</pub-date>
<volume>11</volume>
<issue>2</issue>
<elocation-id>e0149541</elocation-id>
<history>
<date date-type="received">
<day>18</day>
<month>11</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>2</day>
<month>2</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-year>2016</copyright-year>
<copyright-holder>Greninger et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0149541"/>
<abstract>
<p>Fifth-generation cephalosporins, ceftobiprole and ceftaroline, are promising drugs for treatment of bacterial infections from methicillin-resistant <italic>Staphylococcus aureus</italic> (MRSA). These antibiotics are able to bind native PBP2a, the penicillin-binding protein encoded by the <italic>mecA</italic> resistance determinant that mediates broad class resistance to nearly all other beta-lactam antibiotics, at clinically achievable concentrations. Mechanisms of resistance to ceftaroline based on <italic>mecA</italic> mutations have been previously described. Here we compare the genomes of 11 total parent-daughter strains of <italic>Staphylococcus aureus</italic> for which specific selection by serial passaging with ceftaroline or ceftobiprole was used to identify novel non-<italic>mecA</italic> mechanisms of resistance. All 5 ceftaroline-resistant strains, derived from 5 different parental strains, contained mutations directly upstream of the <italic>pbp4</italic> gene (coding for the PBP4 protein), including four with the same thymidine insertion located 377 nucleotides upstream of the promoter site. In 4 of 5 independent ceftaroline-driven selections, we also isolated mutations to the same residue (Asn138) in PBP4. In addition, mutations in additional candidate genes such as <italic>ClpX</italic> endopeptidase, <italic>PP2C</italic> protein phosphatase and transcription terminator <italic>Rho</italic>, previously undescribed in the context of resistance to ceftaroline or ceftobiprole, were detected in multiple selections. These genomic findings suggest that non-<italic>mecA</italic> mechanisms, while yet to be encountered in the clinical setting, may also be important in mediating resistance to 5th-generation cephalosporins.</p>
</abstract>
<funding-group>
<funding-statement>This work was funded in part by NIH (National Institutes of Health) grant R01-AI100291 (to HFC), NIH grant R01-HL105704 (to CYC), and an Abbott Pathogen Discovery Award (to CYC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="1"/>
<table-count count="2"/>
<page-count count="9"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All genomic data from this study have been deposited publicly in NCBI under BioProject PRJNA293093.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>Multi-drug resistant <italic>Staphyloccocus aureus</italic> (MRSA) is a ubiquitous problem in hospitals and in the community [<xref ref-type="bibr" rid="pone.0149541.ref001">1</xref>, <xref ref-type="bibr" rid="pone.0149541.ref002">2</xref>]. The United States Centers for Disease Control and Prevention (CDC) estimates that there are over 75,000 MRSA infections annually [<xref ref-type="bibr" rid="pone.0149541.ref003">3</xref>], with the vast majority occurring in older persons in healthcare-associated settings. Ceftaroline is a fifth-generation cephalosporin with broad-spectrum activity against gram-negative and gram-positive bacteria, including MRSA [<xref ref-type="bibr" rid="pone.0149541.ref004">4</xref>], and is FDA-approved for skin and soft tissue infections, including those caused by MRSA [<xref ref-type="bibr" rid="pone.0149541.ref005">5</xref>, <xref ref-type="bibr" rid="pone.0149541.ref006">6</xref>]. To date, a number of moderately ceftaroline-resistant strains (MIC 4 μg/ml) of MRSA have been described clinically. Moderate ceftaroline resistance has recently been shown to be particularly high among MRSA strains in China and Thailand. High-level ceftaroline resistance is rare, with only one clinical strain to date demonstrating resistance of MIC &gt; 32 μg/ml [<xref ref-type="bibr" rid="pone.0149541.ref007">7</xref>–<xref ref-type="bibr" rid="pone.0149541.ref009">9</xref>]. Whole-genome and candidate gene sequencing have identified Y446N and E447K mutations in the <italic>mecA / pbp2a</italic> gene to be associated with high-level ceftaroline resistance [<xref ref-type="bibr" rid="pone.0149541.ref010">10</xref>, <xref ref-type="bibr" rid="pone.0149541.ref011">11</xref>]. However, whether ceftaroline-associated resistance mutations exist outside of the <italic>mecA / pbp2a</italic> locus remains to be determined.</p>
<p>To discover potential <italic>mecA</italic>-independent resistance mechanisms, we sequenced the genomes of 7 total parent-daughter strains of <italic>S</italic>. <italic>aureus</italic> from which the <italic>mecA</italic> locus had been removed prior to passaging of ceftaroline or ceftobiprole <italic>in vitro</italic>. In addition, we sequenced and analyzed the full genome of a ceftaroline-resistant <italic>mecA</italic> positive strain (CRT) reported to exhibit non-<italic>mecA</italic> mediated ceftaroline resistance [<xref ref-type="bibr" rid="pone.0149541.ref010">10</xref>] in order to elucidate its mechanisms of resistance. Our data reveal a number of mutations in key genes within the <italic>S</italic>. <italic>aureus</italic> genome that are associated with the establishment of high-level resistance to ceftobiprole and ceftaroline.</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="sec003">
<title>Construction of strains</title>
<p>The parental strains for this study include Coln (a <italic>mecA</italic> positive strain) and Colnex and SF8300ex (strains from which the <italic>mecA</italic> gene has been excised) (<xref ref-type="table" rid="pone.0149541.t001">Table 1</xref>). These parental strains were passaged daily 28 days, as previously described [<xref ref-type="bibr" rid="pone.0149541.ref012">12</xref>]. Briefly, 10 ml preparations of trypticase soy broth (TSB) containing various concentrations of antibiotic (ceftaroline or ceftobiprole) were inoculated at a 1:100 dilution with overnight cultures containing 10<sup>9</sup> CFU ml<sup>-1</sup>. The drug concentration was doubled at each passage as tolerated until bacterial growth was observed in at least 128 μg ml<sup>-1</sup> of the drug specified. At the end of passaging, a single clone was chosen randomly for further studies.</p>
<table-wrap id="pone.0149541.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0149541.t001</object-id>
<label>Table 1</label> <caption><title>Strains used in this study and mutations detected in penicillin binding proteins, gdpP and acrB genes.</title></caption>
<alternatives>
<graphic id="pone.0149541.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0149541.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center">Strains</th>
<th align="center">MecA</th>
<th align="center">Driver for selection</th>
<th align="center">MIC to CFTR<xref ref-type="table-fn" rid="t001fn001">*</xref></th>
<th align="center">MIC to AMP<xref ref-type="table-fn" rid="t001fn002">**</xref></th>
<th align="center">MIC to NAF<xref ref-type="table-fn" rid="t001fn003">***</xref></th>
<th align="center">PBP1</th>
<th align="center">PBP2</th>
<th align="center">PBP3</th>
<th align="center"><italic>pbp4</italic> promoter</th>
<th align="center">PBP4</th>
<th align="center">GdpP</th>
<th align="center">AcrB</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center">Coln<xref ref-type="table-fn" rid="t001fn005"><sup>a</sup></xref></td>
<td align="center">(+)</td>
<td align="center"/>
<td align="center">1 S</td>
<td align="center">16 R</td>
<td align="center">128 R</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center">CRT<xref ref-type="table-fn" rid="t001fn004"><sup>#</sup></xref></td>
<td align="center">(+)</td>
<td align="center">CFTR</td>
<td align="center">&gt;64 R</td>
<td align="center">256 R</td>
<td align="center">&gt;256 R</td>
<td align="center"/>
<td align="center">G631S</td>
<td align="center"/>
<td align="center">724602_724603insT (-377); 724500_724590del (-275)</td>
<td align="center">N138K</td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center">Colnex<xref ref-type="table-fn" rid="t001fn006"><sup>b</sup></xref><xref ref-type="table-fn" rid="t001fn004"><sup>#</sup></xref></td>
<td align="center">(-)</td>
<td align="center"/>
<td align="center">&lt;0.25 R</td>
<td align="center">0.25 S</td>
<td align="center">0.5 S</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center">CmTc<xref ref-type="table-fn" rid="t001fn007"><sup>c</sup></xref><xref ref-type="table-fn" rid="t001fn004"><sup>#</sup></xref></td>
<td align="center">(-)</td>
<td align="center">CFTR</td>
<td align="center">&gt;64 R</td>
<td align="center">&gt;256 R</td>
<td align="center">&gt;256 R</td>
<td align="center"/>
<td align="center">D156N</td>
<td align="center"/>
<td align="center">724602_724603insT (-377); 724624T&gt;G (-399)</td>
<td align="center">T201A; F241L</td>
<td align="center">H443Y</td>
<td align="center"/>
</tr>
<tr>
<td align="center">SF8300ex<xref ref-type="table-fn" rid="t001fn008"><sup>d</sup></xref><xref ref-type="table-fn" rid="t001fn004"><sup>#</sup></xref></td>
<td align="center">(-)</td>
<td align="center"/>
<td align="center">0.25 S</td>
<td align="center">0.25 S</td>
<td align="center">0.5 S</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center">SRT<xref ref-type="table-fn" rid="t001fn004"><sup>#</sup></xref></td>
<td align="center">(-)</td>
<td align="center">CFTR</td>
<td align="center">&gt;64 R</td>
<td align="center">&gt;256 R</td>
<td align="center">64 R</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center">716955_716965del (-301)</td>
<td align="center">N138K; H270L</td>
<td align="center">Y306X</td>
<td align="center"/>
</tr>
<tr>
<td align="center">SRB<xref ref-type="table-fn" rid="t001fn004"><sup>#</sup></xref></td>
<td align="center">(-)</td>
<td align="center">CFBP</td>
<td align="center">4 R</td>
<td align="center">4 S</td>
<td align="center">8 S</td>
<td align="center">H499R; E567K</td>
<td align="center">Y437C; V445L; Q453R; M559I</td>
<td align="center">W228X</td>
<td align="center"/>
<td align="center">E183V; F241R</td>
<td align="center">T509A</td>
<td align="center"/>
</tr>
<tr>
<td align="center">Sgap<xref ref-type="table-fn" rid="t001fn009"><sup>e</sup></xref></td>
<td align="center">(-)</td>
<td align="center"/>
<td align="center">0.5 S</td>
<td align="center">&lt;0.25 S</td>
<td align="center">0.5 S</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center">E183A; F241R</td>
<td align="center">N182K</td>
<td align="center">I960V</td>
</tr>
<tr>
<td align="center">SgapT<xref ref-type="table-fn" rid="t001fn004"><sup>#</sup></xref></td>
<td align="center">(-)</td>
<td align="center">CFTR</td>
<td align="center">64 R</td>
<td align="center">&gt;256 R</td>
<td align="center">&gt;256 R</td>
<td align="center">H499R</td>
<td align="center"/>
<td align="center"/>
<td align="center">717031_717032insT (-377)</td>
<td align="center">N138I; E183A; R200L; F241R</td>
<td align="center">N182K</td>
<td align="center">I960V</td>
</tr>
<tr>
<td align="center">Sp<xref ref-type="table-fn" rid="t001fn010"><sup>f</sup></xref></td>
<td align="center">(-)</td>
<td align="center"/>
<td align="center">0.25 S</td>
<td align="center">0.25 S</td>
<td align="center">1 S</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center">E183A; F241R</td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center">SpT<xref ref-type="table-fn" rid="t001fn004"><sup>#</sup></xref></td>
<td align="center">(-)</td>
<td align="center">CFTR</td>
<td align="center">&gt;64 R</td>
<td align="center">&gt;256 R</td>
<td align="center">&gt;256 R</td>
<td align="center"/>
<td align="center">G581D</td>
<td align="center"/>
<td align="center">716675del (-21); 717031_717032insT (-377)</td>
<td align="center">N138I; E183V; T201A; F241R</td>
<td align="center">N214del</td>
<td align="center"/>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>*CFTR = ceftaroline; CLSI breakpoints are ≤1 S, 2 I, ≥4 R (CLSI document M100-S23; ISBN 1-56238-865-7)</p></fn>
<fn id="t001fn002"><p>**AMP = ampicillin; CLSI breakpoints are ≤8 S, ≥16 R (CLSI document M100-S23; ISBN 1-56238-865-7)</p></fn>
<fn id="t001fn003"><p>***NAF = nafcillin; CLSI breakpoints are ≤8 S, ≥16 R (CLSI document M100-S23; ISBN 1-56238-865-7)</p></fn>
<fn id="t001fn004"><p><sup>#</sup>Strains sequenced in this study</p></fn>
<fn id="t001fn005"><p><sup>a</sup>Parental strain of CRT</p></fn>
<fn id="t001fn006"><p><sup>b</sup>Col strain with mecA excised</p></fn>
<fn id="t001fn007"><p><sup>c</sup>Colnex strain containing exogenous mecA plasmid (pYK20); mecA plasmid was evicted after ceftaroline selection (Chan L 2015 AAC)</p></fn>
<fn id="t001fn008"><p><sup>d</sup>SF8300 strain with mecA excised, parental strain of SRT and SRB</p></fn>
<fn id="t001fn009"><p><sup>e</sup>SF8300ex strain in which PBP4 (E183A, F241R), GdpP (N182K) and AcrB (I960V) mutations analogous to those in the CRB strain (Banerjee, et al. 2010 AAC) were introduced</p></fn>
<fn id="t001fn010"><p><sup>f</sup>SF8300ex strain in which PBP4 (E183A, F241R) mutations analogous to those in the CRB strain (Banerjee, et al. 2010 AAC) were introduced</p></fn>
<fn id="t001fn011"><p>Abbreviations: MIC = minimal inhibitory concentration; R = resistant; S = susceptible, susc = susceptibility; CFTR = ceftaroline; CFBP = ceftobiprole.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>The passaged daughter strains include (a) CRT, a ceftaroline-passaged derivative of the Coln strain [<xref ref-type="bibr" rid="pone.0149541.ref010">10</xref>], (b) CmTc, a strain in which a <italic>mecA</italic>-containing plasmid (<italic>pYK20</italic>) was re-introduced into Colnex before passaging in ceftaroline (CmTc) [<xref ref-type="bibr" rid="pone.0149541.ref010">10</xref>], and (c) SRT and SRB, two newly generated strains derived from passaging of SF8300ex in ceftaroline and ceftobiprole, respectively (<xref ref-type="table" rid="pone.0149541.t001">Table 1</xref>). The mutant strain Sgap was created by introducing into SF8300ex select mutations from the <italic>pbp4</italic>, <italic>acrB</italic>, and <italic>gdpP</italic> genes that were identified via whole genome sequencing of a <italic>S</italic>. <italic>aureus</italic> strain selected for high-level ceftobiprole-resistance (CRB) [<xref ref-type="bibr" rid="pone.0149541.ref013">13</xref>]. Daughter strain SgapT was created by passaging the Sgap strain in ceftaroline. Finally, strain SpT was created by passaging in ceftaroline Sp, a mutant SF8300ex strain in which only <italic>pbp4</italic> mutations from strain CRB had been introduced.</p>
<p>Sgap and Sp were included in the study to determine if there were any differences in baseline ceftaroline resistance between a wild-type strain with only <italic>pbp4</italic> mutations (Sp) and a strain with mutations in <italic>pbp4</italic>, <italic>gdpP</italic>, and <italic>acrB</italic> (Sgap). Furthermore, passing of the Sp and Sgap strains were carried out in ceftaroline and subsequently genome sequenced to determine what changes were present in the resistant SpT and SgapT strains.</p>
</sec>
<sec id="sec004">
<title>Genomic DNA extraction</title>
<p>Bacterial cultures incubated in broth overnight (1 mL) were collected by centrifugation and re-suspended in 500 μL buffer containing 50 mM Tris-Cl, pH 8.0, 10 mM EDTA and 100 μg/mL RNase A. Bacterial suspensions were then transferred to Lysing matrix B column (MP Biomedicals) to lyse the bacteria. Bacterial lysates were incubated in ice for 5 min and centrifuged at 14,000<italic>g</italic> for 15 min. Supernatants containing the genomic DNA were transferred to a fresh tube, precipitated using ethanol and re-suspended in sterile water.</p>
</sec>
<sec id="sec005">
<title>Sequencing library preparation</title>
<p>One ng of genomic DNA was used as input for the Nextera XT kit (Illumina), followed by sample barcoding and amplification with 12 cycles of PCR. Libraries were quantified on the Bioanalyzer (Agilent Technologies) and combined in an equimolar mixture. Next-generation sequencing (NGS) libraries were sequenced on a single run on the Illumina MiSeq instrument (300 bp paired-end reads).</p>
</sec>
<sec id="sec006">
<title>Sequencing analysis</title>
<p>Reads were adapter- and quality-trimmed (Q30 cutoff; minimum length &gt;20 nucleotides) using cutadapt [<xref ref-type="bibr" rid="pone.0149541.ref014">14</xref>], followed by re-pairing using pairfq [<xref ref-type="bibr" rid="pone.0149541.ref015">15</xref>]. Paired-end reads were mapped to the reference genomes of <italic>Staphylococcus aureus</italic> COL (NC_002951) or USA300 (CP000730) using Geneious v8.0 [<xref ref-type="bibr" rid="pone.0149541.ref016">16</xref>]. More than 97% of paired-end reads mapped to the reference genomes, with coverage ranging from 138X−287X. High-confidence variants were called using a minimum coverage of 25X and minimum variant frequency of 90%. All called variants were manually reviewed to correct large deletions that were erroneously called as SNPs. Remaining unmapped reads were <italic>de novo</italic> assembled to find genetic elements not present in the reference sequence. Of note, all USA300-based strains <italic>de novo</italic> assembled a ~3,100-bp contig with &gt;99% identity to the <italic>Staphylococcus aureus</italic> SAP046B plasmid (GQ900404), which did not comprise part of the sequenced core genome of <italic>Staphylococcus aureus</italic> USA300 in the National Center for Biotechnology Information (NCBI) GenBank reference database.</p>
</sec>
<sec id="sec007">
<title>Accession Numbers</title>
<p>All genomic data from this study have been deposited publicly in NCBI under BioProject PRJNA293093.</p>
</sec>
</sec>
<sec id="sec008" sec-type="results">
<title>Results</title>
<sec id="sec009">
<title>Four independent selections in ceftaroline result in similar <italic>pbp4</italic> coding and promoter mutations</title>
<p>To identify key genes associated with non-<italic>mecA</italic> mediated ceftaroline resistance in MRSA, we recovered the whole-genome sequences of 2 parental strains and 6 resistant daughter strains that had been passaged in either ceftaroline (n = 5) or ceftobiprole (n = 1) (<xref ref-type="table" rid="pone.0149541.t001">Table 1</xref>). We first examined 6 genes that had been previously implicated in beta-lactam resistance in <italic>Staphylococcus aureus</italic> (<xref ref-type="table" rid="pone.0149541.t001">Table 1</xref>), including <italic>pbp1</italic>, <italic>pbp2</italic>, <italic>pbp3</italic>, <italic>pbp4</italic>, <italic>pbp4</italic> promoter, <italic>gdpP</italic>, and <italic>acrB</italic> [<xref ref-type="bibr" rid="pone.0149541.ref010">10</xref>, <xref ref-type="bibr" rid="pone.0149541.ref017">17</xref>, <xref ref-type="bibr" rid="pone.0149541.ref018">18</xref>].</p>
<p>In the SRT strain, selected in ceftaroline directly from parental strain SF8300ex, 2 coding mutations (N138K and H270L) out of 7 resided in the <italic>pbp4</italic> gene. In addition, an 11-bp deletion at nucleotide position -301 base pairs (bp) was present in the promoter sequence directly upstream of the <italic>pbp4</italic> gene. A premature stop codon was also found in the <italic>gdpP</italic> gene of the SRT strain.</p>
<p>Similarly, mutations in <italic>pbp4</italic> were noted in the CRT strain, which was selected in ceftaroline from a different parental strain (Coln). Two of 8 total coding single nucleotide variants (SNVs) were found to be associated with <italic>pbp4</italic>, including a coding change in the PBP4 protein also seen in SRT (N138K) and a single nucleotide insertion of a thymidine at nucleotide position -377 bp of the <italic>pbp4</italic> promoter (<xref ref-type="supplementary-material" rid="pone.0149541.s001">S1 Table</xref>). The CRT strain also contained a 91 bp deletion in the <italic>pbp4</italic> promoter beginning at nucleotide -274 bp and a G631S mutation in <italic>pbp2</italic>. Outside of the <italic>pbp</italic> genes, two deleted regions 60 bp and 12 bp in length were presented in CRT, resulting in truncations in two metabolic proteins (TdcB and IIABC).</p>
<p>The SgapT strain, also selected in ceftaroline, contained 24 total coding mutations relative to its parental SF8300ex strain. Of these, three of 24 mutations were found in <italic>pbp1</italic> and <italic>pbp4</italic> genes coding for PBP1 and PBP4, respectively. Two of the coding mutations were detected in the <italic>pbp4</italic> gene (N138I and R200L) and a H499R mutation was found in <italic>pbp1</italic>. As in the CRT strain, a single nucleotide insertion of a thymidine at nucleotide position -377 bp was also present in the <italic>pbp4</italic> promoter.</p>
<p>The CmTc strain, derived from parental strain Colnex, had a total of 9 coding mutations. Four of these mutations were mapped to previously identified <italic>mecA</italic>-independent beta-lactam resistance genes [<xref ref-type="bibr" rid="pone.0149541.ref013">13</xref>, <xref ref-type="bibr" rid="pone.0149541.ref019">19</xref>], including two coding mutations in <italic>pbp4</italic> (T201A, F241L), one mutation in <italic>gdpP</italic> (H443Y), and one mutation in <italic>pbp2</italic> (D156N). In addition, the CmTc strain had the same -377 bp thymidine insertion in the <italic>pbp4</italic> promoter as found in CRT and SgapT, as well as a T→G SNV that was not present in any of the other strains.</p>
<p>Comparison of the SpT strain to its grandparent SF8300ex strain demonstrated 24 coding SNVs in total. The SpT strain had four coding changes in the <italic>pbp4</italic> gene; however two of these changes (E183V, F241R) had been deliberately introduced into the parental strain, and the remaining two (N138I, T201A) were acquired SNVs during selection in ceftaroline. In addition, one coding mutation (G581D) was present in <italic>pbp2</italic> and a 3-bp deletion (N214del) was present in the <italic>gdpP</italic> gene. Importantly, as in SRT, CRT, SgapT, and CmTc, mutations in the <italic>pbp4</italic> promoter were present, including a single nucleotide insertion of a thymidine at -377 bp and a single nucleotide deletion of a thymidine at -21 bp.</p>
<p>Across the 5 passaged daughter strains selected in ceftaroline or ceftobiprole, a total of 6 mutations in the <italic>pbp4</italic> gene were identified (N138K, N138I, R200L, T201A, F241L, and H270L). Four of the 5 (80%) ceftaroline selections recovered a mutation to the Asn138 residue of <italic>pbp4</italic> (N138K or N138I). Mapping of the 6 <italic>pbp4</italic> mutations to the PBP4 crystal structure of <italic>Staphylococcus aureus</italic> Col strain in complex with cefotaxime (PDB 3HUM) revealed that all mutations were localized, as expected, to the cephalosporin-binding pocket (<xref ref-type="fig" rid="pone.0149541.g001">Fig 1</xref>). Importantly, all five of the ceftaroline selections also generated mutations to the <italic>pbp4</italic> promoter, with 4 out of 5 (80%) selections demonstrating an identical single nucleotide thymidine insertion at -377 bp.</p>
<fig id="pone.0149541.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0149541.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Mapping of pbp4 gene mutations to the crystal structure of the PBP4 protein of <italic>Staphylococcus aureus</italic> complexed with a cephalosporin antibiotic (cefaxotaxime).</title>
<p>The left panel shows the entire complex, whereas the right panel shows a zoomed image of the cephalosporin binding pocket. The <italic>Staphylococcus aureus</italic> strain depicted in the crystal structure (PDB 3HUM) [<xref ref-type="bibr" rid="pone.0149541.ref030">30</xref>], Col, is the parental strain of the Colnex strain used in the current study (<xref ref-type="table" rid="pone.0149541.t001">Table 1</xref>). Mutant residues in PBP4 identified by selection with ceftaroline or ceftobiprole are highlighted in blue. The ligand marked in yellow is cefotaxime.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0149541.g001" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec010">
<title>Recurrent mutations across multiple selections identify additional candidate genes for <italic>mecA</italic>-independent beta-lactam resistance</title>
<p>After characterizing mutations in the 6 genes known to be associated with beta-lactam resistance genes (Macheboeuf <italic>et al</italic>., 2006, Zapun <italic>et al</italic>., 2008), we next examined remaining coding mutations in other genes that were represented in at least 3 of the 6 ceftaroline or ceftobiprole daughter strains (<xref ref-type="supplementary-material" rid="pone.0149541.s001">S1 Table</xref>). Interestingly, only 3 additional genes met this criterion (<xref ref-type="table" rid="pone.0149541.t002">Table 2</xref>). Strains CmTc, SgapT, and SpT contained coding mutations in transcription termination factor <italic>Rho</italic>. The S14 family endopeptidase <italic>ClpX</italic> and <italic>PP2C</italic> protein phosphatase genes were found mutated in the ceftobiprole-resistant SRB strain as well as the ceftaroline-resistant SRT and SgapT strains. Both SgapT and SRB strains included mutation of the same residue (glycine 169) in the <italic>PP2C</italic> protein phosphatase, a highly conserved MRSA gene on the basis of NCBI conserved domain searches (family cd00143) [<xref ref-type="bibr" rid="pone.0149541.ref020">20</xref>].</p>
<table-wrap id="pone.0149541.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0149541.t002</object-id>
<label>Table 2</label> <caption><title>Additional coding mutations present in at least three selections in this study.</title> <p>Mutated genes from <xref ref-type="table" rid="pone.0149541.t001">Table 1</xref> are not included.</p></caption>
<alternatives>
<graphic id="pone.0149541.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0149541.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center">CmTc</th>
<th align="center">SRT</th>
<th align="center">SRB</th>
<th align="center">SgapT</th>
<th align="center">SpT</th>
<th align="center">Locus tag</th>
<th align="center">Gene</th>
<th align="center">Description</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center"> </td>
<td align="center">Q31X</td>
<td align="center">G169S</td>
<td align="center">G169D</td>
<td align="center"> </td>
<td align="center">USA300HOU_1156</td>
<td align="center"><italic>pp2C</italic></td>
<td align="center">possible PP2C protein phosphatase</td>
</tr>
<tr>
<td align="center"> </td>
<td align="center">P323L</td>
<td align="center">E354fsX358</td>
<td align="center">V381E</td>
<td align="center"> </td>
<td align="center">USA300HOU_1666</td>
<td align="center"><italic>clpX</italic></td>
<td align="center">S14 family endopeptidase ClpX</td>
</tr>
<tr>
<td align="center">F241L</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center">E356V</td>
<td align="center">F83delinsX</td>
<td align="center">USA300HOU_2109</td>
<td align="center"><italic>rho</italic></td>
<td align="center">transcription termination factor Rho</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
</sec>
</sec>
<sec id="sec011" sec-type="conclusions">
<title>Discussion</title>
<p>In this study, we performed whole-genome sequencing of 9 total parent-daughter strains of <italic>S</italic>. <italic>aureus</italic> using an Illumina NGS platform to identify novel mutations associated with high-level, <italic>mecA</italic>-independent resistance to fifth-generation cephalosporins. Notably, all 5 ceftaroline selections generated mutations in the <italic>pbp4</italic> promoter, while 4 of 5 (80%) selections were associated with <italic>pbp4</italic> SNVs coding for a mutation in the ASN138 residue of PBP4. Previously undescribed mutations in additional candidate genes such as <italic>ClpX</italic> endopeptidase, <italic>PP2C</italic> protein phosphatase and termination transcription factor <italic>Rho</italic> were also detected in multiple screens. Our data suggest that mutations in the <italic>pbp4</italic> gene or its promoter are strongly associated with resistance to fifth-generation cephalosporins, although further biochemical characterization will be needed to confirm these findings. These results also illustrate the power of whole-genome sequencing of bacterial isolates to rapidly identify key genetic loci involved in resistance.</p>
<p>Previous work on ceftaroline resistance in <italic>S</italic>. <italic>aureus</italic> has suggested that PBP4 has poor affinity for ceftaroline [<xref ref-type="bibr" rid="pone.0149541.ref019">19</xref>, <xref ref-type="bibr" rid="pone.0149541.ref021">21</xref>–<xref ref-type="bibr" rid="pone.0149541.ref023">23</xref>]. However, loss of the <italic>pbp4</italic> gene has been shown to confer a significant reduction in methicillin resistance, and it has been suggested this may be due to epistatic interactions of PBP4 with PBP2/2a that facilitate resistance to beta-lactam antibiotics [<xref ref-type="bibr" rid="pone.0149541.ref024">24</xref>]. Interestingly, a previously reported MRSA strain PVI [<xref ref-type="bibr" rid="pone.0149541.ref025">25</xref>], which is known to overexpress <italic>pbp4</italic>, is similar to the ceftaroline-resistant strains reported here in that the PVI strain also contains a deletion in the <italic>pbp4</italic> promoter (of size 90 bp) and an adenosine, rather than thymidine, insertion at position -377 bp. This suggests that the <italic>pbp4</italic> promoter mutations isolated in this study may also lead to PBP4 overexpression and promote resistance. Docking analysis of 19 beta-lactams with all available PBP structures identified Asn138 as part of the PBP4 active site (<xref ref-type="fig" rid="pone.0149541.g001">Fig 1</xref>) and, importantly, ceftaroline has higher affinity for PBP4 than the PBP1 and PBP2 proteins [<xref ref-type="bibr" rid="pone.0149541.ref026">26</xref>].</p>
<p>Our genomic sequencing also reveals mutations in new candidate genes such as <italic>ClpX</italic> endopeptidase, <italic>Rho</italic> transcription termination factor and <italic>PP2C</italic> protein phosphatase, and it is plausible that these mutations may contribute to high-level resistance to fifth-generation cephalosporins. Deletion of the <italic>ClpX</italic> gene in MRSA strain USA300 was previously shown to increase the level of resistance to beta-lactam antibiotics [<xref ref-type="bibr" rid="pone.0149541.ref027">27</xref>]. However, this is the first reported identification of mutations in <italic>ClpX</italic> occurring from selection with a beta-lactam antibiotic (ceftaroline / ceftobiprole). The <italic>Rho</italic> transcription termination factor has been shown to be associated with reduced susceptibility to beta-lactam antibiotics, with <italic>Rho</italic>-null mutants demonstrating reduced sensitivity to cephalosporins [<xref ref-type="bibr" rid="pone.0149541.ref028">28</xref>]. Finally, a PP2C-type protein phosphatase (IreP) has been implicated in a signal transduction system that controls cephalosporin resistance in <italic>Enterococcus faecalis</italic> [<xref ref-type="bibr" rid="pone.0149541.ref029">29</xref>].</p>
</sec>
<sec id="sec012">
<title>Supporting Information</title>
<supplementary-material id="pone.0149541.s001" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" position="float" xlink:href="info:doi/10.1371/journal.pone.0149541.s001" xlink:type="simple">
<label>S1 Table</label>
<caption>
<title>All mutations associated with strains analyzed in the current study.</title>
<p>Tabs indicate the changes in a given strain relative to the comparison strain (“SRT-SF8300” refers to changes present in strain SRT when compared to strain SF8300).</p>
<p>(XLSX)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>This work was funded in part by NIH grant R01-AI100291 (to HFC), NIH grant R01-HL105704 (to CYC), and an Abbott Pathogen Discovery Award (to CYC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pone.0149541.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Boucher</surname> <given-names>HW</given-names></name>, <name name-style="western"><surname>Corey</surname> <given-names>GR</given-names></name>. <article-title>Epidemiology of methicillin-resistant Staphylococcus aureus</article-title>. <source>Clinical infectious diseases: an official publication of the Infectious Diseases Society of America</source>. <year>2008</year>;<volume>46</volume> <issue>Suppl 5</issue>:<fpage>S344</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/533590" xlink:type="simple">10.1086/533590</ext-link></comment> <object-id pub-id-type="pmid">18462089</object-id>.</mixed-citation></ref>
<ref id="pone.0149541.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chambers</surname> <given-names>HF</given-names></name>. <article-title>The changing epidemiology of Staphylococcus aureus?</article-title> <source>Emerging infectious diseases</source>. <year>2001</year>;<volume>7</volume>(<issue>2</issue>):<fpage>178</fpage>–<lpage>82</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3201/eid0702.700178" xlink:type="simple">10.3201/eid0702.700178</ext-link></comment> <object-id pub-id-type="pmid">11294701</object-id>; PubMed Central PMCID: PMC2631711.</mixed-citation></ref>
<ref id="pone.0149541.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dantes</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Mu</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Belflower</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Aragon</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Dumyati</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Harrison</surname> <given-names>LH</given-names></name>, <etal>et al</etal>. <article-title>National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011</article-title>. <source>JAMA internal medicine</source>. <year>2013</year>;<volume>173</volume>(<issue>21</issue>):<fpage>1970</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1001/jamainternmed.2013.10423" xlink:type="simple">10.1001/jamainternmed.2013.10423</ext-link></comment> <object-id pub-id-type="pmid">24043270</object-id>.</mixed-citation></ref>
<ref id="pone.0149541.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Beresford</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Biek</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Jandourek</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Mawal</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Riccobene</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Friedland</surname> <given-names>HD</given-names></name>. <article-title>Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections</article-title>. <source>Expert review of clinical pharmacology</source>. <year>2014</year>;<volume>7</volume>(<issue>2</issue>):<fpage>123</fpage>–<lpage>35</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1586/17512433.2014.884457" xlink:type="simple">10.1586/17512433.2014.884457</ext-link></comment> <object-id pub-id-type="pmid">24494793</object-id>.</mixed-citation></ref>
<ref id="pone.0149541.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Corey</surname> <given-names>GR</given-names></name>, <name name-style="western"><surname>Wilcox</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Talbot</surname> <given-names>GH</given-names></name>, <name name-style="western"><surname>Friedland</surname> <given-names>HD</given-names></name>, <name name-style="western"><surname>Baculik</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Witherell</surname> <given-names>GW</given-names></name>, <etal>et al</etal>. <article-title>Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection</article-title>. <source>Clinical infectious diseases: an official publication of the Infectious Diseases Society of America</source>. <year>2010</year>;<volume>51</volume>(<issue>6</issue>):<fpage>641</fpage>–<lpage>50</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/655827" xlink:type="simple">10.1086/655827</ext-link></comment> <object-id pub-id-type="pmid">20695801</object-id>.</mixed-citation></ref>
<ref id="pone.0149541.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>File</surname> <given-names>TM</given-names> <suffix>Jr</suffix></name>, <name name-style="western"><surname>Low</surname> <given-names>DE</given-names></name>, <name name-style="western"><surname>Eckburg</surname> <given-names>PB</given-names></name>, <name name-style="western"><surname>Talbot</surname> <given-names>GH</given-names></name>, <name name-style="western"><surname>Friedland</surname> <given-names>HD</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia</article-title>. <source>Clinical infectious diseases: an official publication of the Infectious Diseases Society of America</source>. <year>2010</year>;<volume>51</volume>(<issue>12</issue>):<fpage>1395</fpage>–<lpage>405</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/657313" xlink:type="simple">10.1086/657313</ext-link></comment> <object-id pub-id-type="pmid">21067350</object-id>.</mixed-citation></ref>
<ref id="pone.0149541.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Alm</surname> <given-names>RA</given-names></name>, <name name-style="western"><surname>McLaughlin</surname> <given-names>RE</given-names></name>, <name name-style="western"><surname>Kos</surname> <given-names>VN</given-names></name>, <name name-style="western"><surname>Sader</surname> <given-names>HS</given-names></name>, <name name-style="western"><surname>Iaconis</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Lahiri</surname> <given-names>SD</given-names></name>. <article-title>Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective</article-title>. <source>The Journal of antimicrobial chemotherapy</source>. <year>2014</year>;<volume>69</volume>(<issue>8</issue>):<fpage>2065</fpage>–<lpage>75</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/jac/dku114" xlink:type="simple">10.1093/jac/dku114</ext-link></comment> <object-id pub-id-type="pmid">24777906</object-id>.</mixed-citation></ref>
<ref id="pone.0149541.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Biedenbach</surname> <given-names>DJ</given-names></name>, <name name-style="western"><surname>Alm</surname> <given-names>RA</given-names></name>, <name name-style="western"><surname>Lahiri</surname> <given-names>SD</given-names></name>, <name name-style="western"><surname>Reiszner</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Hoban</surname> <given-names>DJ</given-names></name>, <name name-style="western"><surname>Sahm</surname> <given-names>DF</given-names></name>, <etal>et al</etal>. <article-title>In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries: AWARE Surveillance Program</article-title>. <source>Antimicrobial agents and chemotherapy</source>. <year>2015</year>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/AAC.01867-15" xlink:type="simple">10.1128/AAC.01867-15</ext-link></comment> <object-id pub-id-type="pmid">26503659</object-id>.</mixed-citation></ref>
<ref id="pone.0149541.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jones</surname> <given-names>RN</given-names></name>, <name name-style="western"><surname>Mendes</surname> <given-names>RE</given-names></name>, <name name-style="western"><surname>Sader</surname> <given-names>HS</given-names></name>. <article-title>Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study</article-title>. <source>The Journal of antimicrobial chemotherapy</source>. <year>2010</year>;<volume>65</volume> <issue>Suppl 4</issue>:<fpage>iv17</fpage>–<lpage>31</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/jac/dkq252" xlink:type="simple">10.1093/jac/dkq252</ext-link></comment> <object-id pub-id-type="pmid">21115451</object-id>.</mixed-citation></ref>
<ref id="pone.0149541.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chan</surname> <given-names>LC</given-names></name>, <name name-style="western"><surname>Basuino</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Diep</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Hamilton</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Chatterjee</surname> <given-names>SS</given-names></name>, <name name-style="western"><surname>Chambers</surname> <given-names>HF</given-names></name>. <article-title>Ceftobiprole- and ceftaroline-resistant methicillin-resistant Staphylococcus aureus</article-title>. <source>Antimicrobial agents and chemotherapy</source>. <year>2015</year>;<volume>59</volume>(<issue>5</issue>):<fpage>2960</fpage>–<lpage>3</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/AAC.05004-14" xlink:type="simple">10.1128/AAC.05004-14</ext-link></comment> <object-id pub-id-type="pmid">25753637</object-id>; PubMed Central PMCID: PMC4394828.</mixed-citation></ref>
<ref id="pone.0149541.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Long</surname> <given-names>SW</given-names></name>, <name name-style="western"><surname>Olsen</surname> <given-names>RJ</given-names></name>, <name name-style="western"><surname>Mehta</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Palzkill</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Cernoch</surname> <given-names>PL</given-names></name>, <name name-style="western"><surname>Perez</surname> <given-names>KK</given-names></name>, <etal>et al</etal>. <article-title>PBP2a mutations causing high-level Ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates</article-title>. <source>Antimicrobial agents and chemotherapy</source>. <year>2014</year>;<volume>58</volume>(<issue>11</issue>):<fpage>6668</fpage>–<lpage>74</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/AAC.03622-14" xlink:type="simple">10.1128/AAC.03622-14</ext-link></comment> <object-id pub-id-type="pmid">25155594</object-id>; PubMed Central PMCID: PMC4249384.</mixed-citation></ref>
<ref id="pone.0149541.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Banerjee</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Gretes</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Basuino</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Strynadka</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Chambers</surname> <given-names>HF</given-names></name>. <article-title>In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureus</article-title>. <source>Antimicrobial agents and chemotherapy</source>. <year>2008</year>;<volume>52</volume>(<issue>6</issue>):<fpage>2089</fpage>–<lpage>96</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/AAC.01403-07" xlink:type="simple">10.1128/AAC.01403-07</ext-link></comment> <object-id pub-id-type="pmid">18378703</object-id>; PubMed Central PMCID: PMCPMC2415812.</mixed-citation></ref>
<ref id="pone.0149541.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Banerjee</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Gretes</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Harlem</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Basuino</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Chambers</surname> <given-names>HF</given-names></name>. <article-title>A mecA-negative strain of methicillin-resistant Staphylococcus aureus with high-level beta-lactam resistance contains mutations in three genes</article-title>. <source>Antimicrobial agents and chemotherapy</source>. <year>2010</year>;<volume>54</volume>(<issue>11</issue>):<fpage>4900</fpage>–<lpage>2</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/AAC.00594-10" xlink:type="simple">10.1128/AAC.00594-10</ext-link></comment> <object-id pub-id-type="pmid">20805396</object-id>; PubMed Central PMCID: PMC2976154.</mixed-citation></ref>
<ref id="pone.0149541.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Martin</surname> <given-names>M</given-names></name>. <article-title>Cutadapt removes adapter sequences from high-throughput sequencing reads</article-title>. <source>EMBnetjournal</source>. <year>2011</year>;<volume>17</volume>(<issue>1</issue>).</mixed-citation></ref>
<ref id="pone.0149541.ref015"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Li H. Pairfq—Research Computing Center Wiki [updated 5 March 2015]. Available: <ext-link ext-link-type="uri" xlink:href="https://wiki.gacrc.uga.edu/wiki/Pairfq" xlink:type="simple">https://wiki.gacrc.uga.edu/wiki/Pairfq</ext-link>. Accessed 17 August 2015.</mixed-citation></ref>
<ref id="pone.0149541.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kearse</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Moir</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Wilson</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Stones-Havas</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Cheung</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Sturrock</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data</article-title>. <source>Bioinformatics</source>. <year>2012</year>;<volume>28</volume>(<issue>12</issue>):<fpage>1647</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/bioinformatics/bts199" xlink:type="simple">10.1093/bioinformatics/bts199</ext-link></comment> <object-id pub-id-type="pmid">22543367</object-id>; PubMed Central PMCID: PMC3371832.</mixed-citation></ref>
<ref id="pone.0149541.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Macheboeuf</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Contreras-Martel</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Job</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Dideberg</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Dessen</surname> <given-names>A</given-names></name>. <article-title>Penicillin binding proteins: key players in bacterial cell cycle and drug resistance processes</article-title>. <source>FEMS Microbiol Rev</source>. <year>2006</year>;<volume>30</volume>(<issue>5</issue>):<fpage>673</fpage>–<lpage>91</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1574-6976.2006.00024.x" xlink:type="simple">10.1111/j.1574-6976.2006.00024.x</ext-link></comment> <object-id pub-id-type="pmid">16911039</object-id>.</mixed-citation></ref>
<ref id="pone.0149541.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zapun</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Contreras-Martel</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Vernet</surname> <given-names>T</given-names></name>. <article-title>Penicillin-binding proteins and beta-lactam resistance</article-title>. <source>FEMS Microbiol Rev</source>. <year>2008</year>;<volume>32</volume>(<issue>2</issue>):<fpage>361</fpage>–<lpage>85</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1574-6976.2007.00095.x" xlink:type="simple">10.1111/j.1574-6976.2007.00095.x</ext-link></comment> <object-id pub-id-type="pmid">18248419</object-id>.</mixed-citation></ref>
<ref id="pone.0149541.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Leski</surname> <given-names>TA</given-names></name>, <name name-style="western"><surname>Tomasz</surname> <given-names>A</given-names></name>. <article-title>Role of penicillin-binding protein 2 (PBP2) in the antibiotic susceptibility and cell wall cross-linking of Staphylococcus aureus: evidence for the cooperative functioning of PBP2, PBP4, and PBP2A</article-title>. <source>Journal of bacteriology</source>. <year>2005</year>;<volume>187</volume>(<issue>5</issue>):<fpage>1815</fpage>–<lpage>24</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JB.187.5.1815–1824.2005" xlink:type="simple">10.1128/JB.187.5.1815–1824.2005</ext-link></comment> <object-id pub-id-type="pmid">15716453</object-id>; PubMed Central PMCID: PMC1064008.</mixed-citation></ref>
<ref id="pone.0149541.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Das</surname> <given-names>AK</given-names></name>, <name name-style="western"><surname>Helps</surname> <given-names>NR</given-names></name>, <name name-style="western"><surname>Cohen</surname> <given-names>PT</given-names></name>, <name name-style="western"><surname>Barford</surname> <given-names>D</given-names></name>. <article-title>Crystal structure of the protein serine/threonine phosphatase 2C at 2.0 A resolution</article-title>. <source>The EMBO journal</source>. <year>1996</year>;<volume>15</volume>(<issue>24</issue>):<fpage>6798</fpage>–<lpage>809</lpage>. <object-id pub-id-type="pmid">9003755</object-id>; PubMed Central PMCID: PMC452505.</mixed-citation></ref>
<ref id="pone.0149541.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kosowska-Shick</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>McGhee</surname> <given-names>PL</given-names></name>, <name name-style="western"><surname>Appelbaum</surname> <given-names>PC</given-names></name>. <article-title>Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae</article-title>. <source>Antimicrobial agents and chemotherapy</source>. <year>2010</year>;<volume>54</volume>(<issue>5</issue>):<fpage>1670</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/AAC.00019-10" xlink:type="simple">10.1128/AAC.00019-10</ext-link></comment> <object-id pub-id-type="pmid">20194704</object-id>; PubMed Central PMCID: PMC2863635.</mixed-citation></ref>
<ref id="pone.0149541.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mendes</surname> <given-names>RE</given-names></name>, <name name-style="western"><surname>Deshpande</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Smyth</surname> <given-names>DS</given-names></name>, <name name-style="western"><surname>Shopsin</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Farrell</surname> <given-names>DJ</given-names></name>, <name name-style="western"><surname>Jones</surname> <given-names>RN</given-names></name>. <article-title>Characterization of methicillin-resistant Staphylococcus aureus strains recovered from a phase IV clinical trial for linezolid versus vancomycin for treatment of nosocomial pneumonia</article-title>. <source>Journal of clinical microbiology</source>. <year>2012</year>;<volume>50</volume>(<issue>11</issue>):<fpage>3694</fpage>–<lpage>702</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JCM.02024-12" xlink:type="simple">10.1128/JCM.02024-12</ext-link></comment> <object-id pub-id-type="pmid">22972817</object-id>; PubMed Central PMCID: PMC3486224.</mixed-citation></ref>
<ref id="pone.0149541.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moisan</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Pruneau</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Malouin</surname> <given-names>F</given-names></name>. <article-title>Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae</article-title>. <source>The Journal of antimicrobial chemotherapy</source>. <year>2010</year>;<volume>65</volume>(<issue>4</issue>):<fpage>713</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/jac/dkp503" xlink:type="simple">10.1093/jac/dkp503</ext-link></comment> <object-id pub-id-type="pmid">20097788</object-id>.</mixed-citation></ref>
<ref id="pone.0149541.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Memmi</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Filipe</surname> <given-names>SR</given-names></name>, <name name-style="western"><surname>Pinho</surname> <given-names>MG</given-names></name>, <name name-style="western"><surname>Fu</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Cheung</surname> <given-names>A</given-names></name>. <article-title>Staphylococcus aureus PBP4 is essential for beta-lactam resistance in community-acquired methicillin-resistant strains</article-title>. <source>Antimicrobial agents and chemotherapy</source>. <year>2008</year>;<volume>52</volume>(<issue>11</issue>):<fpage>3955</fpage>–<lpage>66</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/AAC.00049-08" xlink:type="simple">10.1128/AAC.00049-08</ext-link></comment> <object-id pub-id-type="pmid">18725435</object-id>; PubMed Central PMCID: PMC2573147.</mixed-citation></ref>
<ref id="pone.0149541.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Henze</surname> <given-names>UU</given-names></name>, <name name-style="western"><surname>Berger-Bachi</surname> <given-names>B</given-names></name>. <article-title>Penicillin-binding protein 4 overproduction increases beta-lactam resistance in Staphylococcus aureus</article-title>. <source>Antimicrobial agents and chemotherapy</source>. <year>1996</year>;<volume>40</volume>(<issue>9</issue>):<fpage>2121</fpage>–<lpage>5</lpage>. <object-id pub-id-type="pmid">8878592</object-id>; PubMed Central PMCID: PMC163484.</mixed-citation></ref>
<ref id="pone.0149541.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kumar</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Anitha</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Sivasakthi</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Bag</surname> <given-names>S</given-names></name>, <string-name>P l</string-name>, <string-name>A A</string-name>, <etal>et al</etal>. <article-title>In silico study of penicillin derivatives and cephalosporins for upper respiratory tract bacterial pathogens</article-title>. <source>3 Biotech</source>. <year>2014</year>;<volume>4</volume>:<fpage>241</fpage>–<lpage>51</lpage>.</mixed-citation></ref>
<ref id="pone.0149541.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Baek</surname> <given-names>KT</given-names></name>, <name name-style="western"><surname>Grundling</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Mogensen</surname> <given-names>RG</given-names></name>, <name name-style="western"><surname>Thogersen</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Petersen</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Paulander</surname> <given-names>W</given-names></name>, <etal>et al</etal>. <article-title>beta-Lactam resistance in methicillin-resistant Staphylococcus aureus USA300 is increased by inactivation of the ClpXP protease</article-title>. <source>Antimicrobial agents and chemotherapy</source>. <year>2014</year>;<volume>58</volume>(<issue>8</issue>):<fpage>4593</fpage>–<lpage>603</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/AAC.02802-14" xlink:type="simple">10.1128/AAC.02802-14</ext-link></comment> <object-id pub-id-type="pmid">24867990</object-id>; PubMed Central PMCID: PMC4136064.</mixed-citation></ref>
<ref id="pone.0149541.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lee</surname> <given-names>YH</given-names></name>, <name name-style="western"><surname>Helmann</surname> <given-names>JD</given-names></name>. <article-title>Mutations in the primary sigma factor sigmaA and termination factor rho that reduce susceptibility to cell wall antibiotics</article-title>. <source>Journal of bacteriology</source>. <year>2014</year>;<volume>196</volume>(<issue>21</issue>):<fpage>3700</fpage>–<lpage>11</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JB.02022-14" xlink:type="simple">10.1128/JB.02022-14</ext-link></comment> <object-id pub-id-type="pmid">25112476</object-id>; PubMed Central PMCID: PMC4248801.</mixed-citation></ref>
<ref id="pone.0149541.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kristich</surname> <given-names>CJ</given-names></name>, <name name-style="western"><surname>Little</surname> <given-names>JL</given-names></name>, <name name-style="western"><surname>Hall</surname> <given-names>CL</given-names></name>, <name name-style="western"><surname>Hoff</surname> <given-names>JS</given-names></name>. <article-title>Reciprocal regulation of cephalosporin resistance in Enterococcus faecalis</article-title>. <source>mBio</source>. <year>2011</year>;<volume>2</volume>(<issue>6</issue>):<fpage>e00199</fpage>–<lpage>11</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/mBio.00199-11" xlink:type="simple">10.1128/mBio.00199-11</ext-link></comment> <object-id pub-id-type="pmid">22045988</object-id>; PubMed Central PMCID: PMC3202758.</mixed-citation></ref>
<ref id="pone.0149541.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Navratna</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Nadig</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Sood</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Prasad</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Arakere</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Gopal</surname> <given-names>B</given-names></name>. <article-title>Molecular basis for the role of Staphylococcus aureus penicillin binding protein 4 in antimicrobial resistance</article-title>. <source>Journal of bacteriology</source>. <year>2010</year>;<volume>192</volume>(<issue>1</issue>):<fpage>134</fpage>–<lpage>44</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JB.00822-09" xlink:type="simple">10.1128/JB.00822-09</ext-link></comment> <object-id pub-id-type="pmid">19854906</object-id>; PubMed Central PMCID: PMC2798245.</mixed-citation></ref>
</ref-list>
</back>
</article>